Orexo captures 4% opioid dependence market share within year of Zubsolv launch
Emerging Swedish addiction specialist company Orexo has achieved success by capturing a 4% share by volume of the US opioid dependence market a year after its launch of lead product Zubsolv (buprenorphine and naloxone). Research from investment intelligence firm Edison Equity Research has shown the company is continuing with its initiatives to drive further growth through market share gains and market expansion.
These efforts are being supported by ongoing market access improvements, clinical data enabling physician education and the potential approval of a label extension in the third quarter of 2015.
The company is also positioning itself for the future, with operational restructuring and financial strengthening providing greater flexibility to evaluate wider pipeline opportunities, potentially with partners, which includes the commercialization of Zubsolv outside the USA, and Phase III-ready pain program OX51.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze